お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
425901

世界の鬱治療市場の調査と分析

Global Depression Treatment Therapy Market Research and Forecast, 2018-2023

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.93円
世界の鬱治療市場の調査と分析
出版日: 2018年03月06日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の鬱治療市場について調査分析を行い、市場概要、市場動向、競合状況などについて考察するとともに、地域別に市場を分析、企業プロファイルなどについて包括的に分析し、まとめています。

第1章 レポートのサマリー

  • 調査方法とツール
  • 市場の概要

第2章 市場概要と考察

  • 定義
  • ギャップ分析
  • 実績分析
  • 現在の市場動向
  • アナリストによる考察
  • 規制
  • 鬱病の種類

第3章 市場決定因子

  • 市場促進因子
  • 市場抑制因子
  • 市場機会

第4章 メンタルヘルス市場の分析

第5章 市場セグメンテーション

  • 鬱病の種類別
  • 鬱病薬市場
  • 鬱病治療装置市場

第6章 競合状況

  • 主要戦略分析
  • 主要企業分析

第7章 地域別分析

  • 北米
  • 欧州
  • アジア太平洋地域
  • 世界のその他の諸国

第8章 企業プロファイル

図表

List of Tables

  • TABLE # 1 GLOBAL DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023, ($ MILLION)
  • TABLE # 2 GLOBAL DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DEPRESSION TYPE 2017-2023, ($ MILLION)
  • TABLE # 3 GLOBAL SAD MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 4 GLOBAL MAJOR DEPRESSION MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 5 GLOBAL DYSTHYMIA DISORDER MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 6 GLOBAL POSTPARTUM DEPRESSION MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 7 GLOBAL ATYPICAL DEPRESSION MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 8 GLOBAL PSYCHOTIC DEPRESSION MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 9 GLOBAL BIPOLAR DISORDER MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 10 GLOBAL DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DRUGS TYPE 2017-2023, ($ MILLION)
  • TABLE # 11 GLOBAL DEPRESSION TREATMENT THERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY SSRIS 2017-2023, ($ MILLION)
  • TABLE # 12 GLOBAL FLUOXETINE MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 13 GLOBAL SERTRALINE MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 14 GLOBAL ESCITALOPRAM MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 15 GLOBAL OTHER SSRIS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 16 GLOBAL DEPRESSION TREATMENT THERAPY DRUGS MARKET RESEARCH AND ANALYSIS BY ATYPICAL ANTIDEPRESSANTS 2017-2023, ($ MILLION)
  • TABLE # 17 GLOBAL BUPROPION MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 18 GLOBAL DULOXETINE MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 19 GLOBAL VENLAFAXINE MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 20 GLOBAL DESVENLAFEXINE MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 21 GLOBAL OTHER ATYPICAL ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 22 GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
  • TABLE # 23 GLOBAL DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DEPRESSION TREATMENT DEVICE 2017-2023, ($ MILLION)
  • TABLE # 24 GLOBAL TRANSCRANIAL MAGNETIC MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 25 GLOBAL DEEP BRAIN STIMULATOR MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 26 GLOBAL VIRTUAL REALITY THERAPY MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 27 GLOBAL VAGUS NERVE SIMULATOR MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 28 GLOBAL SMARTPHONE APPLICATIONS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 29 GLOBAL OTHER DEVICES MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
  • TABLE # 30 NORTH AMERICA DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DEPRESSION TYPE 2017-2023, ($ MILLION)
  • TABLE # 31 NORTH AMERICA DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DRUGS TYPE 2017-2023, ($ MILLION)
  • TABLE # 32 NORTH AMERICA DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DEPRESSION TREATMENT DEVICE 2017-2023, ($ MILLION)
  • TABLE # 33 EUROPE DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DEPRESSION TYPE 2017-2023, ($ MILLION)
  • TABLE # 34 EUROPE DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DRUGS TYPE 2017-2023, ($ MILLION)
  • TABLE # 35 EUROPE DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DEPRESSION TREATMENT DEVICE 2017-2023, ($ MILLION)
  • TABLE # 36 APAC DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DEPRESSION TYPE 2017-2023, ($ MILLION)
  • TABLE # 37 APAC DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DRUGS TYPE 2017-2023, ($ MILLION)
  • TABLE # 38 APAC DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DEPRESSION TREATMENT DEVICE 2017-2023, ($ MILLION)
  • TABLE # 39 REST OF THE WORLD DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DEPRESSION TYPE 2017-2023, ($ MILLION)
  • TABLE # 40 REST OF THE WORLD DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DRUGS TYPE 2017-2023, ($ MILLION)
  • TABLE # 41 REST OF THE WORLD DEPRESSION TREATMENT THERAPY MARKET RESEARCH AND ANALYSIS BY DEPRESSION TREATMENT DEVICE 2017-2023, ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL DEPRESSION TREATMENT THERAPY MARKET SHARE BY DEPRESSION TYPE 2017 VS 2023 (IN %)
  • FIGURE # 2 GLOBAL DEPRESSION TREATMENT THERAPY MARKET SHARE BY DRUGS TYPE 2017 VS 2023 (IN %)
  • FIGURE # 3 GLOBAL DEPRESSION TREATMENT THERAPY MARKET SHARE BY DEPRESSION TREATMENT DEVICE 2017 VS 2023 (IN %)
  • FIGURE # 4 GLOBAL DEPRESSION TREATMENT THERAPY MARKET SHARE BY GEOGRAPHY 2017 VS 2023 (IN %)
  • FIGURE # 5 NORTH AMERICA DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 6 US DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 7 CANADA DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 8 EUROPEAN DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 9 UK DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 10 FRANCE DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 11 GERMANY DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 12 ITALY DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 13 SPAIN DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 14 ROE DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 15 ASIA PACIFIC DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 16 INDIA DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 17 CHINA DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 18 JAPAN DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 19 ROAPAC DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 20 REST OF THE WORLD DEPRESSION TREATMENT THERAPY MARKET SIZE 2017-2023 ($MILLION)
目次
Product Code: PHM-1302

Global depression treatment market is facing stiff decline. The market is expected to grow at low CAGR of 2.1% for the forecasted period of 2018-2023. One of the major factors for such low growth is a rapid decline in the revenue of branded drug manufacturers and growing strength of generic drug manufacturers. The patent cliff has caused a decline in revenues ranging from few million dollars to billions. The patent expiration and generic drug manufacturers gaining license to manufacturers have forced many branded drug manufacturers to either stop their R&D or to reduce budgets. There are very limited number of new drugs in the pipeline. Decline in revenues is majorly due to fall in the price of once expensive drugs by over 50-90%. Volume shipment is still high and increasing especially in emerging markets.

However, markets for therapies using medical devices such as Vagus nerve stimulation, deep brain stimulation, and smartphones is rising. The devices market is expected to grow at a CAGR of 9.2%. The introduction of virtual reality in the treatment of disorders such as post-traumatic stress disorders is also driving the market.

North America and Europe currently are the leading markets. They make up for 70% of the total depression treatment market. The markets are driven by high awareness regarding depression and availability of drugs and therapies. However, the patent cliff has caused a decline in the growth rates of the market. Asia Pacific will have the highest growth rate. Recently the discussion over effects of depression on the economies has been going on. Countries such as India, China and Japan are spending on the research of new treatment methods for treating depression. It is expected that new Asian companies could develop new branded drugs in the near future.

The key players included in the report are: Pfizer, Teva Pharmaceuticals, Johnson and Johnson, Merck & Co., Eli lily and company, Novartis, Sanofi-Aventis, AstraZeneca, and others.

Global depression treatment therapy market by depression type

Global depression treatment therapy market by drugs type

Global depression treatment therapy market by depression treatment device

RESEARCH METHODOLOGY

The market study of depression market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:

Financial reports of companies involved in the market

Authentic Public Databases

Whitepapers, research-papers and news blogs

Company websites and their product catalogue.

Supplier Websites such as Alibaba, amazon for pricing analysis.

The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.

The Report covers:

Comprehensive research methodology of Global depression treatment therapy Market.

This report also includes detailed and extensive market overview with Analyst insights & key market trends.

Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the Global depression treatment therapy Market.

Insights about market determinants which are stimulating the Global depression treatment therapy Market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. REPORT SUMMARY

1.1. RESEARCH METHODS AND TOOLS

1.2. MARKET BREAKDOWN

1.2.1. BY SEGMENTS

1.2.2. BY GEOGRAPHY

1.2.3. BY STAKEHOLDERS

2. MARKET OVERVIEW AND INSIGHTS

2.1. DEFINITION

2.2. GAP ANALYSIS

2.3. HISTORICAL ANALYSIS

2.4. CURRENT MARKET TRENDS

2.5. ANALYST INSIGHTS & CURRENT MARKET TRENDS

2.5.1. KEY FINDINGS

2.5.2. RECOMMENDATION

2.5.3. CONCLUSION

2.6. REGULATIONS

2.6.1. TAX LAWS

2.6.1.1. UNITED STATES

2.6.1.2. EUROPEAN UNION

2.6.1.3. CHINA

2.6.1.4. INDIA

2.6.1.5. REST OF THE WORLD

2.6.2. DRUG REGULATIONS

2.6.2.1. UNITED STATES

2.6.2.2. EUROPEAN UNION

2.6.2.3. CHINA

2.6.2.4. INDIA

2.6.2.5. REST OF THE WORLD

2.6.3. TYPE OF DEPRESSION DISORDERS

2.6.3.1. MAJOR DEPRESSION

2.6.3.2. BIPOLAR DEPRESSION

2.6.3.3. SEASONAL AFFECTIVE DISORDER

2.6.3.4. PSYCHOTIC DEPRESSION

2.6.3.5. POSTPARTUM DEPRESSION

2.6.3.6. ATYPICAL DEPRESSION

2.6.3.7. PERSISTENT DEPRESSIVE DISORDER

3. MARKET DETERMINANT

3.1. MOTIVATORS

3.1.1. HIGH OCCURRENCE OF MENTAL HEALTH DISORDERS

3.1.2. INCREASING AWARENESS RELATED TO MENTAL HEALTH DISORDERS

3.1.3. UP SURGING MARKET FOR CHEAPER GENERIC DRUGS

3.1.4. UNHEALTHY LIFESTYLES RESULT IN THE INCREASED SALE OF ANTI-DEPRESSANTS

3.2. RESTRAINTS

3.2.1. HIGH COST OF THERAPIES

3.2.2. SIDE EFFECTS OF DEPRESSION DRUGS

3.2.3. EXPIRING PATENTS AND DRYING PIPELINES

3.3. OPPORTUNITIES

3.3.1. EMERGING MARKETS

3.3.2. INTRODUCTION OF NEW THERAPIES SUCH AS VIRTUAL REALITY

4. MARKET SEGMENTATION

4.1. DEPRESSION TREATMENT THERAPY MARKET BY DEPRESSION TYPE

4.1.1. SEASONAL AFFECTIVE DISORDER (SAD)

4.1.2. MAJOR DEPRESSION

4.1.3. DYSTHYMIA DISORDER

4.1.4. POSTPARTUM DEPRESSION

4.1.5. ATYPICAL DEPRESSION

4.1.6. PSYCHOTIC DEPRESSION

4.1.7. BIPOLAR DISORDER

4.2. DEPRESSION TREATMENT THERAPY MARKET BY DRUGS TYPE

4.2.1. SELECTIVE SEROTONIN REUPTAKE INHIBITORS

4.2.1.1. FLUOXETINE (PROZAC)

4.2.1.2. SERTRALINE (ZOLOFT)

4.2.1.3. ESCITALOPRAM (LEXAPRO)

4.2.1.4. OTHERS SSRIS

4.2.2. ATYPICAL ANTIDEPRESSANTS

4.2.2.1. BUPROPION (WELLBUTRIN)

4.2.2.2. DULOXETINE (CYMBALTA)

4.2.2.3. VENLAFAXINE (EFFEXOR)

4.2.2.4. DESVENLAFEXINE (PRISTIQ)

4.2.2.5. OTHERS ATYPICAL ANTIDEPRESSANTS

4.2.3. TRICYCLIC ANTIDEPRESSANTS

4.3. DEPRESSION TREATMENT THERAPY MARKET BY DEPRESSION TREATMENT DEVICE

4.3.1. TRANSCRANIAL MAGNETIC

4.3.2. DEEP BRAIN STIMULATOR

4.3.3. VIRTUAL REALITY THERAPY

4.3.4. VAGUS NERVE SIMULATOR

4.3.5. SMART PHONE APPLICATIONS

4.3.6. OTHERS DEVICES

5. COMPETITIVE LANDSCAPE

5.1. MARKET SHARE ANALYSIS

5.2. KEY COMPANY ANALYSIS

6. REGIONAL ANALYSIS

6.1. NORTH AMERICA

6.1.1. UNITED STATES

6.1.2. CANADA

6.1.3. REST OF NORTH AMERICA

6.2. EUROPE

6.2.1. UNITED KINGDOM

6.2.2. FRANCE

6.2.3. GERMANY

6.2.4. ITALY

6.2.5. SPAIN

6.2.6. REST OF EUROPE

6.3. ASIA PACIFIC

6.3.1. INDIA

6.3.2. CHINA

6.3.3. JAPAN

6.4. REST OF THE WORLD

7. COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.2. ALLERGAN PLC

7.3. ASTRAZENECA

7.4. BRAIN RESOURCE COMPANY (BRC)

7.5. BRAINSWAY LTD.

7.6. BRISTOL MYERS SQUIBB

7.7. CYBERONICS, INC

7.8. ELECTROMEDICAL PRODUCTS INTERNATIONAL, INC.

7.9. ELI LILLY AND COMPANY

7.10. JOHNSON & JOHNSON

7.11. LANNETT CO INC

7.12. LIFECARE NEURO PRODUCTS LIMITED

7.13. H. LUNDBECK A/S

7.14. MAGVENTURE

7.15. MAYO CLINIC

7.16. MERCK & CO.

7.17. NEUROSIGMA, INC.

7.18. NEURONETICS

7.19. NOVARTIS

7.20. OTSUKA PHARMACEUTICALS

7.21. PFIZER

7.22. ROCHE HOLDING AG

7.23. SANOFI-AVENTIS

7.24. SILVER OAK HEALTH

7.25. SUN PHARMACEUTICAL INDUSTRIES LTD.

7.26. TAKEDA PHARMACEUTICALS

7.27. TEVA PHARMACEUTICALS

7.28. THERAPY CHARLOTTE LLC

7.29. VALEANT PHARMACEUTICALS INTERNATIONAL

7.30. VISTAGEN THERAPEUTICS, INC.

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.